LLY240712P750000
- 0.06
- 0.000.00%
Eli Lilly and Co Newsroom
Eli Lilly, Novo Nordisk Shares Dip as Pfizer Ramps Up Diabetes Drug Competition
Shares of $Eli Lilly and Co(LLY.US)$ and $Novo-Nordisk A/S(NVO.US)$ finished lower on Thursday, perhaps influenced by competitive developments and regulatory updates in the pharmaceutical sector.
Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$197.36 Million in Common Stock
$Eli Lilly and Co(LLY.US)$ 10% Shareholder LILLY ENDOWMENT INC sold 210K shares of common stock on Jul 10, 2024 at an average price of $939.816 for a total value of $197.36 million.Source:
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Senator Bernie Sanders expressed confidence that Novo Nordisk A/S (NYSE:NVO) can be persuaded to reduce the U.S. prices of its popular weight-loss drugs, Ozempic and Wegovy, by publicly highlighting
Eli Lilly Price Target Raised to $1000.00/Share From $850.00 by Berenberg
Eli Lilly Price Target Raised to $1000.00/Share From $850.00 by
Berenberg Maintains Buy on Eli Lilly and Co, Raises Price Target to $1000
Berenberg analyst Kerry Holford maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $850 to $1000.
Tesla Is a 'Faith-based Stock' With Fundamentals Not Grounded in the Near-term - DataTrek
Express News | Shares of Lilly and Novo Nordisk Are Trading Lower After Pfizer Selected Its Preferred Once-daily Modified Release Formulation for Danuglipron, a GLP-1 Receptor Agonist
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
Lilly, DaVita, Illumina Among Top Healthcare Quant Picks Ahead of Q2 Earnings
Eli Lilly Is Maintained at Overweight by JP Morgan
Eli Lilly Is Maintained at Overweight by JP
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,000 to $1,083
On Jul 11, major Wall Street analysts update their ratings for $Eli Lilly and Co(LLY.US)$, with price targets ranging from $1,000 to $1,083.Morgan Stanley analyst Terence Flynn maintains with a buy
Eyeing the "weight loss fever," Pfizer (PFE.US) is quickly developing oral medication: conducting mid-stage research in the second half of the year.
Pfizer is developing a weight loss drug, trying to break into the multi-billion dollar weight loss market.
Pfizer Moves Forward With Weight-Loss Pill. The Stock Is Rising. -- Barrons.com
By Angela Palumbo Pfizer stock was rising Thursday after the pharmaceutical company said it was moving forward with the development of its once-daily weight-loss pill following promising data.
Pfizer Advances Development of Once-daily Weight-loss Pill
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating
Eli Lilly and Co. (LLY) has an average rating of outperform and price targets ranging from $540 to $1,083, according to analysts by Capital IQ.Price: 943.51, Change: +3.73, Percent Change: +0.40
Express News | Eli Lilly : JP Morgan Raises Target Price to $1,000 From $900
Express News | Barclays Maintains Overweight on Eli Lilly and Co, Raises Price Target to $1025
Eli Lilly and Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 9.18% Barclays $913 → $1025 Maintains Overweight 07/05/2024 8.97% Morgan Stanley $1023 → $1023
Jim Cramer Reviews 8 Companies That Could Top $1 Trillion in Market Cap
CNCB's Jim Cramer on Wednesday reviewed eight stocks that could join the coveted "trillion-dollar stock club," pinpointing Eli Lilly and Tesla as top contenders. Also on the list are Berkshire Hathaway, JPMorgan, Broadcom, Walmart, Visa and Exxon Mobil.
Express News | Sanders Says Will Introduce Bill to Expand Medicare Drug Price Negotiations, Extend Annual Out-of-Pocket Cap Outside of Medicare